Detalhe da pesquisa
1.
Determinants of activity and efficacy of anti-PD1/PD-L1 therapy in patients with advanced solid tumors recruited in a clinical trials unit: a longitudinal prospective biomarker-based study.
Cancer Immunol Immunother
; 72(6): 1709-1723, 2023 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-36625938
2.
Correction to: Determinants of activity and efficacy of anti-PD1/PD-L1 therapy in patients with advanced solid tumors recruited in a clinical trials unit: a longitudinal prospective biomarker-based study.
Cancer Immunol Immunother
; 72(6): 1725-1726, 2023 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-36809405
3.
SAMHD1 expression is a surrogate marker of immune infiltration and determines prognosis after neoadjuvant chemotherapy in early breast cancer.
Cell Oncol (Dordr)
; 47(1): 189-208, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-37667113
4.
CAR affinity modulates the sensitivity of CAR-T cells to PD-1/PD-L1-mediated inhibition.
Nat Commun
; 15(1): 3552, 2024 Apr 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-38670972
5.
A 14-gene B-cell immune signature in early-stage triple-negative breast cancer (TNBC): a pooled analysis of seven studies.
EBioMedicine
; 102: 105043, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38447275
6.
HER2DX ERBB2 mRNA expression in advanced HER2-positive breast cancer treated with T-DM1.
J Natl Cancer Inst
; 115(3): 332-336, 2023 03 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-36576009
7.
Unexpected Durable Complete Response With Anti-PD-L1 Blockade in Metastatic Undifferentiated Pleomorphic Sarcoma: A Case Report With Host and Tumor Biomarker Analysis.
JCO Precis Oncol
; 7: e2300051, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37856765